Xuan Gu Bao·2025-06-19 12:11Suspension - The controlling shareholder and actual controller are planning a change in control, leading to the suspension of the stock [1] Mergers and Acquisitions - Kangda New Materials plans to acquire at least 51% of Zhongke Huami in cash to expand into the semiconductor integrated circuit field [2] Equity Transfer, Increase, and Buyback - Shanghai Sanmao's controlling shareholder, Light Textile Group, intends to transfer 95% of its shares in Shanghai Sanmao to Electromechanical Group without compensation, resulting in a change of control [3] - Qianhong Pharmaceutical's actual controller's concerted actor, Wang Ke, plans to increase holdings by no less than 12.4 million shares [3] - Novogene plans to repurchase company shares with an investment of between 5 million and 10 million yuan [4] External Investment and Daily Operations - Huitong Energy's subsidiary plans to invest 30 million yuan in an industrial fund focusing on hard technology in the semiconductor and intelligent manufacturing sectors [5] - Ningbo Ocean plans to invest 2 billion yuan in the construction of four 4300 TEU container ships [6] - Saiseng Pharmaceutical signed a technology transfer contract for the NeoAB33 new drug project with its affiliated company, with a total transaction amount of 20 million yuan [6] - Xiamen Tungsten's subsidiary, Baotou Jinlong, has completed the construction and production of a 5000-ton high-performance neodymium-iron-boron magnetic material project [7] - Hengrun Co., Ltd. plans to invest 1.2 billion yuan in a project to produce 2,000 sets of wind power gearbox components annually [8] - Diweier plans to invest in the construction of a precision manufacturing project for deep-sea pressure components, with an estimated total investment of 305.8 million yuan [9] - Haizheng Pharmaceutical intends to establish a joint venture for synthetic biology [10] - Shanjin International has authorized management to initiate preparations for the overseas issuance of H shares and listing in Hong Kong [11] - Wantai Biological's freeze-dried varicella attenuated live vaccine (VZV-7D) has started Phase III clinical trials and completed the enrollment of the first subject [12] Performance Changes - Saintno Biological expects a year-on-year increase in net profit of 254%-332% for the first half of the year, driven by strong performance in its peptide raw material drug business [13]